author-photo

Ruchi Hamal

Tufts Medical Center

6

Papers

6

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

Alternative chemoradiotherapy in anal carcinoma patients with mutations in thymidylate synthase and dihydropyrimidine dehydrogenase genes

2021 Therapeutic Advances in Gastroenterology
Show All
- Source
- Cite
- Save
Citations (0)
Chloroma of the Bladder: A Case Report of Leukemia Progression Presenting as Hematuria

2021 Case Reports in Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Pharmacogenetic Variants in the DPYD and TYMS Genes are Clinically Significant Predictors of Fluoropyrimidine Toxicity: Are We Ready for Use in our Clinical Practice.

2020
Show All
- Source
- Cite
- Save
Citations (3)
Alternative chemoradiotherapy to treat locally advanced (LA) anal carcinoma (AC) in patients (pts) with mutations in thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) genes: A case series.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among pts with 5-FU/capecitabine (CAP)-related adverse events (AEs): Experience of 2 decades.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Association of thymidylate synthase (TYMS) polymorphism with adverse events (AEs) of 5-FU/capecitabine (CAP) in pts with GI cancers.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)